Log In
BCIQ
Print this Print this
 

Sanctura XR

  Manage Alerts
Collapse Summary General Information
Company Endo International plc
DescriptionOnce-daily formulation of Sanctura trospium chloride
Molecular Target Muscarinic receptor
Mechanism of ActionMuscarinic receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationIncontinence
Indication DetailsTreat overactive bladder (OAB)
Regulatory Designation
PartnerAllergan plc;
Mylan N.V.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/05/2009

Undisclosed

0

0

Get a free BioCentury trial today